We identified four differentially abundant factors in plasma (p<0.01) between NSCLC and SCLC patients, vascular epithelial growth factor-A (VEGF-A, p<0.0001), interleukin 17E (IL-17E, p<0.0001), and interferon alpha2 (IFN-α2, p = 0.0089) were elevated in NSCLC patients and interleukin 1 receptor antagonist (IL-1RA, p = 0.0006) was lower in NSCLC patients (Fig 4). This evidence concerns the gene IL25 and small cell lung carcinoma.